Post-earnings recap
Reported
Tue, Aug 14, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite reporting a loss per share, Soleno Therapeutics saw a positive stock reaction, rising 4.18%. This increase may reflect investor optimism regarding the company's future plans and ongoing projects. The lack of revenue data and guidance indicates uncertainty, but management's comments suggest they are focused on improving operations and advancing their pipeline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management remains cautiously optimistic about the company's future prospects. They emphasized their commitment to advancing their therapeutic programs.
Management expressed hope for future developments in their pipeline.
They highlighted ongoing efforts to enhance operational efficiency.